Roivant Sciences (ROIVW) Stock News, Sep 2023-Jan 2024

ROIVW Nasdaq

01/30/2024 04:05 PM

News

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

-

12/20/2023 04:30 PM

News

Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

-

12/14/2023 09:00 AM

News

Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

11/28/2023 07:00 AM

News

Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

-

11/27/2023 08:00 AM

News

Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

-

11/13/2023 07:00 AM

News

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

11/10/2023 08:00 AM

News

Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

-

10/30/2023 05:30 PM

News

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

-

10/23/2023 01:00 AM

News

Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

09/26/2023 06:00 AM

News

Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

Rhea-AI Summary

Summary not available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags